A handful of discovered-in-China candidates have entered the global clinic, including a few first-in-class contenders.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Trends and Characteristics of New Drug Approvals in China, 2011–2021
Therapeutic Innovation & Regulatory Science Open Access 02 November 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Chinese biopharma starts feeding the global pipeline. Nat Rev Drug Discov 16, 443–446 (2017). https://doi.org/10.1038/nrd.2017.94
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.94
This article is cited by
-
Trends and Characteristics of New Drug Approvals in China, 2011–2021
Therapeutic Innovation & Regulatory Science (2023)
-
Novel Drugs Targeting the Epigenome
Current Pharmacology Reports (2017)